Testing immune therapy put into the belly for cancer fluid
Treatments studied
Part of Cancer clinical trials.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer fluid in the belly (malignant ascites) confirmed by a test of tissue or cells, from stomach, pancreatic, or bile-duct adenocarcinoma
- Your belly fluid is more than 1000 mL
- You have not had treatment placed into the belly for this fluid before (including belly-cavity procedures for treatment)
- You can likely live at least 4 weeks, and you can get blood counts checked showing platelets are at least 50,000
- You do not have an active infection or known bleeding disorder, and you don’t have serious heart/lung problems or recent heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
This trial tests a drug called tocilizumab, which is given through the tube that drains fluid from your chest or belly. The goal is to see if it can help control cancer-related fluid buildup and improve symptoms.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.